Similarly, EpCAM upregulation of AKT downstream targets promotes stemness and DNA loss repair in breast cancer cells, thereby enhancing resistance to radiotherapy and DNA-damaging chemotherapeutic agents (such as doxorubicin, cisplatin, or gemcitabine) [141]. The gene discussed is AKT1; the disease is breast cancer.